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Calcium oxalate crystallization in urine: Role of urate and glycosami-
noglycans. Increasing the concentration of urate promotes the crystal-
lization of calcium oxalate in human urine. In this study the possibility
that this effect might be attributable to the attenuation of the inhibitory
activity of urinary glycosaminoglycans (GAGs) was explored. Urine
samples were collected from 20 men with no history of urolithiasis and
the intact GAGs removed by 10 kDa ultrafiltration. Ten of these
specimens, designated type A, spontaneously precipitated calcium
oxalate crystals when the median urate concentration was increased
from 3.13 to 7.33 mmollliter by the addition of a saturated solution of
sodium urate. In the remaining more dilute urines, which were desig-
nated type B, spontaneous calcium oxalate crystallization did not occur
when the median urate concentration was raised from 2.20 to 6.40
mmol/liter. In these samples crystallization was induced by a standard
load of oxalate above the empirically determined metastable limit.
Addition of urate significantly reduced the median metastable limit from
the control value of 125 to 46 mol oxalate, and the volume of calcium
oxalate deposited was increased fourfold from 25,000 to 104,000 m3/
tl. The median size of the precipitated particles was also increased in
the presence of urate from 12.06 m to 14.3 m; this was confirmed by
scanning electron microscopy, which demonstrated that the crystals
precipitated in the presence of added urate, though individually smaller,
were markedly more numerous and more highly aggregated than those
deposited in the control. Re-ultrafiltration of the urines to which urate
had been added did not alter the urate concentration, and SEM
examination of the ultrafiltration membranes did not reveal the pres-
ence of any particulate material. It was concluded that urate does not
exist in urine in a colloidal or crystalline form, and that the promotion
of calcium oxalate crystallization by urate is not a consequence of its
reducing the inhibitory activity of GAGs or other urinary macromol-
ecules.
A number of theories have been advanced to explain the
apparent association between urate excretion and calcium
oxalate stone formation. One of these [1] submits that gly-
cosaminoglycans (GAGs) are the principal inhibitors of crystal-
lization present in human urine, and that colloidal particles of
urate bind to urinary GAGs, thereby abolishing or attenuating
their inhibitory potency and indirectly increasing the risk of
calcium oxalate crystal nucleation, growth and aggregation in
vivo.
A number of observations lend credence to this theory:
GAGs [2, 3], particularly chondroitin sulphate [4], the most
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abundant GAG in human urine, have been shown to bind to
sodium urate crystals. Further, incubation with crystalline
urate has been reported to decrease the inhibitory activity of
heparin [5—7], dilute macromolecular urine fractions [8, 9] and
dilute unfractionated urine [7]. However, the theory is under-
mined by observations that the inhibitory activity of undiluted
urine is unaltered by reductions in the endogenous urate con-
centration [10, 11] and by pre-incubation with crystalline mono-
sodium urate [12], and by the lack of concensus regarding the
presence of colloidal urate in urine [13—15].
In confirmation of earlier reports [16—18] it has recently been
shown that increasing the concentration of urate in human urine
promotes the crystallization of calcium oxalate [19]. This in-
crease was achieved by the addition to urine samples of a
solution of sodium urate which had been filtered and which
therefore would not have contained microscopic particles of
sodium urate. However, the possibility remains that the in-
crease in urate concentration may have brought about the
formation of colloidal particles of urate in the urine, which then
indirectly promoted calcium oxalate crystallization by inacti-
vating the endogenous GAGs molecules, as proposed by Rob-
ertson, Knowles and Peacock [1]. If such a mechanism is
responsible for the reported promotion of calcium oxalate
crystallization by urate [16—19], then urate's effects should not
be observed in the absence of urinary GAGs. Thus the aim of
this study was to examine the effect of increasing the urate
concentration in urine samples from which all the intact GAGs
had been removed by ultrafiltration.
Methods
Collection and ultrafiltration of urine samples
Twenty-four-hour urine specimens were collected from 20
healthy men (mean age 36 years) who had no history of kidney
stone disease. The samples were refrigerated without preserva-
tive for the duration of the collection. Each specimen was then
centrifuged at 8,000 x g for 15 minutes at 20°C. The supernatant
was filtered through 0.22 pm Millipore filters and then ultrafil-
tered using an Amicon hollow fiber bundle (H1P1O-20, Amicon
Corporation, Lexington, Massachusetts, USA) with a nominal
molecular weight cut-off of 10,000 daltons.
Preparation of ura re-enriched urine specimens
This procedure has been described in detail elsewhere [19].
Briefly, each ultrafiltered urine sample prepared above was
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titrated against sodium urate solution to determine the maxi-
mum increase in urate concentration that could be achieved
before causing spontaneous precipitation of sodium urate. The
sample was then divided. To the test sample a ifitered (0.22 m)
saturated solution of sodium urate dissolved in 1 mol/liter
NaOH was added so as to increase its urate concentrations to
1.3 mmollliter less than the amount determined above. In
practical terms, this meant that the urate concentration was
increased by an average of 3 to 4 mmollliter. The remaining
portion of the sample was used as the control, and to this was
added an identical volume of 1 mollliter NaOH.
While adding the sodium urate or NaOH solution, the pH was
carefully controlled with concentrated HC1 so that the native
value was never exceeded. All samples were then adjusted to
their original value, and the osmolalities of the control and
experimental samples were matched exactly by the addition of
solid NaC1. Both the control and urate-enriched urines were left
to stand for 90 minutes at 37°C and then checked for the
presence of crystals by light microscopy and Coulter Counter
particle analysis.
As was observed with urine samples which had not been
ultrafiltered [19], two types of urine specimens were observed.
Those designated type A spontaneously precipitated calcium
oxalate immediately upon the addition of the urate solution.
The remaining type B samples did not precipitate calcium
oxalate, and in these crystallization was induced by the oxalate
load technique described below.
Crystallization experiments
The experimental system used for assessing crystal growth
and aggregation in urine has been described in detail previously
[201. In brief, the first part of the technique involves the
empirical determination of the metastable limit of the urine with
respect to calcium oxalate. This is defined as the minimum
amount of oxalate required to elicit spontaneous detectable
calcium oxalate crystal nucleation, and is determined by titrat-
ing the urine sample with sodium oxalate solution, followed by
incubation at 37°C for 30 minutes in a shaking water bath. The
Coulter Counter is then used to detect crystals> 2 m. Once
the metastable limit has been determined, a standard load of
oxalate (30 smolJl00 ml) in excess of this amount is added
dropwise to the sample in a shaking water bath at 37°C and
parameters of crystallization are measured using the Coulter
Counter. These include the volume of crystalline material
deposited during a 90 minute incubation period, and the size of
the crystals and aggregates produced. Each experiment was
performed in duplicate.
As has been previously reported [21, 22], ultrafiltration did
not alter the metastable limits of the urine samples.
Scanning electron microscopy
At the end of each experiment, 1.0 ml aliquots were filtered
(0.22 Lm) and the filter dried overnight at 37°C; it was mounted
on an aluminium stub and gold-spluttered for 180 seconds (SEM
Autocoating Unit E5200, Polaron Equipment Ltd). Stubs were
examined using an ETEC Auto Scan Electron Microscope
(Siemens AG) at an operating voltage of 20 kV.
Table 1. Biochemical data for type A and type B urine specimens
Type A Type B
Median Range Median Range
pH 6.14 6.10—6.47 6.18 6.12—6.32
Na 213 124—344 162 126—221
Ca 4.7 2.5—7.2 1.55 1.2—3.0
Mg 3.6 2.5—6,4 1.3 1.2—3.4
Pyrophosphate 0.011 0.004—0.018 0.008 0.002—0.012
Urate 3.2 1.8—5.0 2.1 1.6—3.4
Creatinine 10.6 5.8—16.7 8.0 4.5—10.8
Oxalate 0.40 0.24—0.88 0.23 0.16-0.32
Citrate 2.30 1.41—4.62 1.67 0.19—2.84
Relative 6.47 3.85—10.22 1.94 1.08—3.42
saturation
Apart from pH and relative saturation, all values are expressed as
mmol/liter.
Re-ultrafiltration of urate-enriched urines
For these experiments an additional eight ultrafiltered urine
samples of type B were prepared and the urate concentration of
each was increased as described in above. The samples were
then incubated at 37°C for 90 minutes. A 50 ml portion of each
ultrafiltered urate-enriched urine was then re-ultrafiltered using
a Diaflo ultrafiltration membrane (YM 10, Amicon Corpora-
tion), with the urate concentration being measured before and
after re-ultrafiltration. After re-ultrafiltration, the membranes
were examined for the presence of colloidal or crystalline
particles using scanning electron microscopy as described
above.
Biochemical measurements
Urinary GAGs were measured by the method of Blumen-
krantz and Asboe-Hansen [23]. Uric acid was determined by a
standard (phosphotungstic acid) Technicon SMA autoanalyzer
system, which has a lower limit of urate detection of 0.02
mmol/liter. All other urine constituents and relative saturation
indices with respect to calcium oxalate were measured as
described previously [19].
Statistical methods
Data were compared using the Wilcoxon signed rank sum
Results
test.
Biochemical composition and relative saturation indices of
type A and type B urines
Table 1 shows the biochemical data for the type A and type B
urines. The pH values of the urines did not differ, but the
concentrations of the constituents of the type B samples tended
to be less than those of the type A. Despite the lower concen-
trations in the type B urines, there was still a great deal of
overlap between the values in the two groups. However, when
the relevant data were combined to compute relative saturation
indices for the urines, there was a clear distinction between the
values in the type A (all> 3.8) and type B (all <3.4).
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Ultrafiltration significantly reduced (P < 0.01) the median
GAGs concentration from 58.48 to 21.32 p,g/ml, while the
addition of soluble urate increased the median urinary urate
concentration from 3.13 to 7.33 mmol/liter (P <0.01). All urines
spontaneously precipitated calcium oxalate crystals on the
addition of urate, increasing the median volume of particulate
material (P < 0.01) from the background value of 400 to 15,200
sm3/.d (Fig. 1). Scanning electron microscopy of the precip-
itated material (Fig. 2) revealed the exclusive deposition of
aggregates of calcium oxalate dihydrate crystals; urate crystals
were never detected. No crystals were detected in control urine
samples.
Effect of urate on calcium oxalate crystallization in type B
urines
Ultrafiltration of the type B urines significantly reduced (P <
0.01) their median GAGs concentration from 49 to 13.5 jsg/ml.
Addition of the urate solution increased the median urinary
urate concentration from 2.2 to 6.4 mmollliter and significantly
(P < 0.01) lowered their metastable limits from the median
control value of 125 mol of oxalate to 46 smol, as illustrated in
Figure 3.
As was observed previously with urine samples which had
not been ultrafiltered [191, despite the addition of a significantly
smaller total exogenous oxalate load to the samples enriched
with urate, the bulk of crystalline material deposited in these
samples was markedly higher than in the controls. Figure 4
shows that the median volume of crystalline material deposited
in the control urines, 25,000 1sm3/d, was significantly (P <0.01)
Fig. 2. A typical scanning electron micrograph of calcium oxalate
dihydrate crystals precipitated in response to increasing the urate
concentration in a type A urine sample.
increased to 104,000 m3/d; this represents a fourfold increase
in the amount of crystalline material deposited.
The median size of the crystalline material deposited in the
urate-enriched urines was also increased (P < 0.01) from 12.0 to
14.3 sm (Fig. 5) and this is reflected in the scanning electron
micrographs shown in Figure 6. Crystalline deposits consisted
exclusively of calcium oxalate monohydrate and were clustered
into large aggregates in the control samples. In contrast, the
individual crystals deposited from the same urines enriched
with urate were markedly smaller, more numerous and more
highly aggregated.
Effect of re-ultrafiltration on the urate concentration of urate-
enriched urines
Re-ultrafiltration of the ultrafiltered urines after addition of
the urate did not significantly change their urate concentration
(Fig. 7). Furthermore, examination of the ultrafiltration mem-
branes by scanning electron microscopy did not reveal any
crystalline or colloidal material.
Discussion
In a previous study we showed that increasing the concen-
tration of urate in urine samples which had been centrifuged and
filtered markedly promoted calcium oxalate crystallization [19].
In this paper we have explored the possibility that this may
have resulted from a reduction in the inhibitory potency of
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Fig. 1. The volume of calcium oxalate crystals deposited in the type A
control urines and samples of the same urines which had been supple-
mented with urate. P < 0.01.
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endogenous GAGs, consequent upon their binding to colloidal
urate particles [1], by studying the effect of urate on calcium
oxalate crystallization in urines which had been ultrafiltered by
passage through a hollow fiber bundle with a nominal molecular
weight cut-off of 10 kba.
The inhibitory potency of GAGs has been suggested to
depend on their charge density [24] and their structural integrity
[25]. Intact GAGs have molecular weights ranging from 20 to 50
kDa [24] and most should have been removed by 10 kDa
ultrafiltration. However, analysis of the urines before and after
ultrafiltration revealed that their removal was incomplete, This
can probably be attributed to the assay used; color formation
with this technique [23] relies on the presence of uronic acid
residues, and so GAG fragments of <10 kDa would have been
detected. Human urine has been reported to contain GAGs of a
spectrum of molecular weights [26—28], so that their complete
removal by ultrafiltration is virtually impossible [29]. Nonethe-
less, the predominant GAGs in human urjne are chondroitin
sulphatcs and non-sulphated chondroitin [29, 30] whose molec-
ular weights are of the order of 20 to 50 kDa [26]. Thus, most of
the intact urinary GAGs would have been removed by ultrafil-
tration. On the other hand, they are not removed by low speed
centrifugation and Millipore filtration (unpublished observa-
tions from our laboratory). Thus the urine samples used in our
previous study [19] where we demonstrated the promotory
effect of urate on calcium oxalate crystallization in spun and
Millipore filtered urine would have contained their full comple-
ment of GAGs. If the theory of Robertson et al [1] were correct,
then one would eçpect that in urines from which the intact
GAGs had been removed by ultrafiltration, increasing the urate
concentratiop would have no effect on calcium oxalate crystal-
lization; control urines containing no added urate should give
identical results to the same urines enriched with urate. How-
ever, because removal of the GAGs was incomplete in the
present study, it could be argued that the amount of GAG
fragments <10 kDa remaining after ultrafiltration was sufficient
to explain the enhanced crystallization of calcium oxalate in the
urines to which urate had been added. This possibility is
unlikely: the reduction in GAGs concentration, though incom-
plete, was considerable, and if GAGs were an important con-
tributor to the potency of urate's effects, then the promotion of
calcium oxalate crystallization by urate should be correspond-
ingly less in wines containing significantly less GAGs. How-
ever, results obtained using the ultrafiltere4 urine samples were
virtually identical to those observed previously with the spun
and filtered urines [19]. Furthermore, it has recently been
shown that chondroitin sulphate js not a significant inhibitor of
calcium oxalate crystallization in ultrafiltered urine [22].
Increasing the concentration of urate by 3 to 4 mmollliter
caused spontaneous precipitation of calcium oxalate crystals in
some urine samples (type A), but not in others (type B), which
required the addition of oxalate to induce crystallization. The
categorization of a urine as type A or B was shown not to
depend upon the individual concentrations of a number of
relevant urinary constituents, such as calcium, oxalate, citrate,
etc., but rather to be a function of the computed relative
saturation of the urine with respect to calcium oxalate. The
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Fig. 3. The metastable limits with respect to calcium oxalate in type B
control urines and samples of the same urines to which urate had been
added. P C 0.01.
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Fig. 4. The volume of crystalline material deposited following the
addition of a standard load of oxalate to type B control urines and
samples of the same urines enriched with urate. P C 0.01.
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A B
Fig. 6. Scanning electron micro graphs of typical crystals precipitated
from a control type B ultrafiltered urine sample (panel A), and from the
same sample to which urate had been added (panel B).
relative saturation of a urine is the ratio of the activity product
of calcium oxalate in the sample to its thermodynamic solubility
product. Although the thermodynamic solubility product can
measured in pure inorganic solutions, activity values must be
obtained by calculation, taking into account all possible ionic
interactions. Since urine is a complex mixture of ions, relative
saturation can only be determined by computation: a relative
saturation index <1 indicates undersaturation, 1, saturation,
and >1, supersaturation. In this study type A urines all had
relative saturation indices greater than 3.8, whereas type B
samples all had indices less than 3.4. This clear-cut difference
would explain the spontaneous precipitation of calcium oxalate
pD p
p
in the type A urines but not in the type B. Nonetheless, as was
observed previously with the spun and filtered urine specimens
[19], although spontaneous precipitation of calcium oxalate did
not occur in the type B urines, their metastable limits with
respect to calcium oxalate were significantly reduced to less
than half that of the controls in the presence of added urate.
And, as was also observed previously, despite the addition of a
significantly smaller oxalate load, the volume of crystalline
material deposited in the urines enriched with urate was in-
creased fourfold relative to the controls and the crystalline
particles were significantly larger. However, the difference
between the sizes of the particles deposited in the control and
test urines was not as marked as was seen between the spun and
filtered urines and their controls, presumably because the
crystals precipitated from ultrafiltered urines tend to be more
aggregated than those from spun and filtered samples [21, 22].
This was again confirmed by scanning electron microscopic
examination of the crystalline material, which revealed the
precipitation of calcium oxalate monohydrate crystals in both
the control and test portions of each urine. The crystals
deposited from the control ultrafiltered urines were large and
highly aggregated, unlike those precipitated from the spun and
filtered samples [19], which were almost entirely single. And as
was also seen in the earlier study, though the individual crystals
were considerably smaller in the urate-enriched urines, they
were far more numerous than in the controls, testifying to the
fact that urate had enhanced the nucleation of calcium oxalate.
Noteworthy also is the fact that crystals of sodium urate were
never seen.
Taken together, the results obtained with ultrafiltered and
spun and filtered urines are virtually indistinguishable. It may
be therefore concluded that urate does not act on GAGs, or
indeed any other urinary macromolecule to produce its promo-
tory effect. This is further substantiated by the re-ultrafiltration
studies. As discussed above, ultrafiltration effectively removes
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Fig. 7. The urate concentration of the type B urines which had been
supplemented with urate, before and after re-ultrafiltration.
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Fig. 5. The size of the crystalline particles, expressed as the position of
the mode of the volume distribution curve, precipitated from the type B
control urines and samples of the same urines after supplementation
with urate. P < 0.01.
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intact GAGs, which have been reported to stabilize urate in a
colloidal form [311 and prevent its precipitation. Therefore
removal of GAGs by ultrafiltration would be expected to
encourage the precipitation of particles of this salt in urines
loaded with urate. However, it can be concluded from the
results presented here that no such particles were formed.
Urate concentrations of the ultrafiltered urines which had been
supplemented with this salt were not significantly changed by
re-ultraffitration of the samples, and scanning electron micros-
copy of the ultrafiltration membranes did not reveal the pres-
ence of any colloidal or crystalline particles. Thus, the results
presented in this paper do not support the notion that urate
exists in a colloidal form in urine. Although Pak et al [13], using
hollow fiber cartridges with a nominal molecular weight cut-off
of 5000 Da, reported the presence of colloidal urate in urine,
others using 1000 Da ultrafiltration discs could not substantiate
the observation [14, 15]. Furthermore, Bowyer et al [32J were
unable to demonstrate that sodium urate exhibits colloidal
properties in aqueous buffered solutions. Since the credibility of
the GAGs-urate theory depends absolutely on the existence in
urine of colloidal urate, the lack of evidence for a ubiquitous
occurrence of colloidal urate must create some doubt as to its
relevance in vivo.
Taking all these considerations into account, it is apparent
that the promotion of calcium oxalate crystallization observed
upon addition of sodium urate to urine cannot be ascribed to a
reduction in inhibitory activity caused by the binding of urinary
GAGs to colloidal particles of sodium urate. The possibility
remains, however, that urate's effect may be attributable to
either of the mechanisms of epitaxy [33] or salting-out [171, and
these will be the subjects of further reports from our laboratory.
Reprint requests to Rosemary L. Ryall, Ph.D., Department of
Surgery, Flinders Medical Centre, Bedford Park, South Australia 5042,
Australia.
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